



Published in final edited form as:

*Hum Genet.* 2010 March ; 127(3): 325–336. doi:10.1007/s00439-009-0777-8.

## Examination of *FGFRL1* as a candidate gene for diaphragmatic defects at chromosome 4p16.3 shows that *Fgfr1* null mice have reduced expression of *Tpm3*, sarcomere genes and *Lrtm1* in the diaphragm

**Nelson LopezJimenez,**

Division of Genetics, Department of Pediatrics, University of California, 533 Parnassus St, Room U585P, San Francisco, CA 94143-0748, USA

**Simon D. Gerber,**

Department of Clinical Research, University of Bern, Murtenstrasse 35, PO Box 43, 3010 Bern, Switzerland

**Vlad Popovici,**

Swiss Institute of Bioinformatics, University of Lausanne, 1015 Lausanne, Switzerland

**Sonia Mirza,**

Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of California, 2340 Sutter St. S174, Box 0875, 94115 San Francisco, USA

**Kirsten Copren,**

Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of California, 2340 Sutter St. S174, Box 0875, 94115 San Francisco, USA

**Linda Ta,**

Genomics Core, The J. David Gladstone Institutes, 1650 Owens St, San Francisco, CA 94158, USA

**Gary M. Shaw,**

Department of Pediatrics, Stanford University School of Medicine, 251 Campus Drive Rm x159, Stanford, CA 94305, USA

**Beat Trueb,** and

Department of Clinical Research, University of Bern, Murtenstrasse 35, PO Box 43, 3010 Bern, Switzerland

**Anne M. Slavotinek**

Division of Genetics, Department of Pediatrics, University of California, 533 Parnassus St, Room U585P, San Francisco, CA 94143-0748, USA

Anne M. Slavotinek: slavotia@peds.ucsf.edu

### Abstract

*Fgfr1* (also known as *Fgfr5*; OMIM 605830) homozygous null mice have thin, amuscular diaphragms and die at birth because of diaphragm hypoplasia. *FGFRL1* is located at 4p16.3, and this

---

© Springer-Verlag 2009

Correspondence to: Anne M. Slavotinek, slavotia@peds.ucsf.edu.

**Electronic supplementary material** The online version of this article (doi:10.1007/s00439-009-0777-8) contains supplementary material, which is available to authorized users.

chromosome region can be deleted in patients with congenital diaphragmatic hernia (CDH). We examined *FGFRL1* as a candidate gene for the diaphragmatic defects associated with 4p16.3 deletions and re-sequenced this gene in 54 patients with CDH. We confirmed six known coding single nucleotide polymorphisms (SNPs): c.209G > A (p.Pro20Pro), c.977G > A (p.Pro276Pro), c.1040T > C (p.Asp297Asp), c.1234C > A (p.Pro362Gln), c.1420G > T (p.Arg424Leu), and c.1540C > T (p.Pro464Leu), but we did not identify any gene mutations. We genotyped additional CDH patients for four of these six SNPs, including the three non-synonymous SNPs, to make a total of 200 chromosomes, and found that the allele frequency for the four SNPs, did not differ significantly between patients and normal controls ( $p \geq 0.05$ ). We then used Affymetrix Genechip<sup>®</sup> Mouse Gene 1.0 ST arrays and found eight genes with significantly reduced expression levels in the diaphragms of *Fgfr11* homozygous null mice when compared with wildtype mice—*Tpm3*, *Fgfr11* ( $p = 0.004$ ), *Myl2*, *Lrtm1*, *Myh4*, *Myl3*, *Myh7* and *Heph11*. *Lrtm1* is closely related to *Slit3*, a protein associated with herniation of the central tendon of the diaphragm in mice. The *Slit* proteins are known to regulate axon branching and cell migration, and inhibition of *Slit3* reduces cell motility and decreases the expression of *Rac* and *Cdc42*, two genes that are essential for myoblast fusion. Further studies to determine if *Lrtm1* has a similar function to *Slit3* and if reduced *Fgfr11* expression can cause diaphragm hypoplasia through a mechanism involving decreased myoblast motility and/or myoblast fusion, seem indicated.

## Introduction

In recent years, array comparative genomic hybridization has been used to map chromosome regions that contain genes required for normal diaphragm formation (Slavotinek et al. 2006; Kantarci et al. 2006; Scott et al. 2007). These array studies and previous cytogenetic case reports have shown that monosomy for distal chromosome 4p16 can be associated with congenital diaphragmatic hernia (CDH; for review of chromosome aberrations at 4p16 and CDH, see Holder et al. 2007). Deletions of 4p16 are also associated with Wolf–Hirschhorn syndrome (WHS), and there are several reports of WHS patients who have had terminal deletions of chromosome 4p and CDH (Tachdjian et al. 1992; Howe et al. 1996; Sergi et al. 1998; van Dooren et al. 2004; Van Buggenhout et al. 2004; Casaccia et al. 2006; Slavotinek et al. 2006; Table 1). The smallest chromosome 4p16.3 deletion associated with a diaphragmatic defect was 2.4 Mb in size and extends from chromosome 4pter to probe D4S43 (Casaccia et al. 2006). The recurrent deletions in WHS patients with CDH establish the 4p16.3 terminal region as highly likely to contain a gene that is involved in diaphragm development, with the critical region being the terminal 2.4 Mb of 4p16.3 as described above (Casaccia et al. 2006). However, CDH is not invariably associated with WHS and terminal 4p16.3 deletions, and there are reports of WHS patients with deletions encompassing *FGFRL1* in whom CDH was not noted (Engbers et al. 2009).

We used Endeavour and TOPPgene gene prioritization software to examine the terminal 2.4 Mb of chromosome 4p16.3 for candidate genes for CDH. Although the results returned from both programs were not entirely in agreement, *Fgfr11* (also known as *Fgfr5*; OMIM 605830; Wiedemann and Trueb 2000; Kim et al. 2001; Sleeman et al. 2001) returned as a possible candidate gene from the two separate programs (Table 2). *Fgfr11* has seven exons, of which the last six are coding exons. Early in murine development at E10.5, *Fgfr11* is present in the brain, cranial placodes, pharyngeal arches, somites and heart (Catela et al. 2009). At E15–E17, *Fgfr11* is expressed throughout the diaphragm and the intercostal and tongue muscles (Trueb and Taeschler 2006). The gene is also highly expressed in nasal, rib and tracheal cartilage and in the intermediate cartilage from bone primordia (Trueb et al. 2003; Trueb and Taeschler 2006). Although the exact function of *Fgfr11* is unknown, the protein forms constitutive dimers and promotes cell adhesion mediated by heparan sulfate, a glycosaminoglycan of the extracellular matrix (Rieckmann et al. 2008). *Fgfr11* also binds *Fgf2*, a stimulator of muscle

cell proliferation, although it does so with a lower binding affinity than *Fgfr2* (Sleeman et al. 2001).

*Fgfr11* homozygous null mice have been created by removing the first two exons of *Fgfr11*, and the mutant mice were found to have thin and amuscular diaphragms (Baertschi et al. 2007). These mice did not have diaphragmatic hernias, but at E18.5, the liver was pushed tightly against the dorsal and costal regions of the diaphragm to form a small protrusion and the dorsal and costal ends of the diaphragms had a thickness of 60% of the wildtype diaphragms (Baertschi et al. 2007). The muscle hypotrophy was specific to the diaphragm and the remaining muscles in the *Fgfr11* null mice were normal (Baertschi et al. 2007). A second mouse model of *Fgfr11* loss of function was also made by deleting exons 3–7 of *Fgfr11* (Catela et al. 2009). This mutant was described as having the same diaphragm defects as previously reported (Baertschi et al. 2007; Catela et al. 2009), reduced growth, skeletal anomalies resembling those found in the WHS phenotype in humans, a reduction in laryngeal cartilage size, cardiac defects with faulty septation of the heart, anemia and mal-development of the yolk sac (Catela et al. 2009). In both mouse models of loss of *Fgfr11* function, heterozygotes were normal (Catela et al. 2009). In *Danio rerio*, depletion of the *Fgfr11a* and *Fgfr11b* genes caused malformations of the lower jaw and inhibited the development of cartilage formed by the branchial arches (Hall et al. 2006). *FGFRL1* has therefore been implicated in the pathogenesis of the craniofacial anomalies found in WHS (Catela et al. 2009; Engbers et al. 2009).

We asked if *FGFRL1* was implicated in the pathogenesis of CDH associated with 4p16.3 deletions and WHS. We re-sequenced *FGFRL1* in patients with CDH and normal controls and performed expression arrays on cDNA obtained from the diaphragms of homozygous null and wildtype mice. The following paper describes our results.

## Materials and methods

### Gene prioritization software

We used Endeavour (<http://homes.esat.kuleuven.be/~bioiuser/endeavour/endeavour.php>) and TOPPgene prioritization software (<http://toppgene.cchmc.org/>). For training or comparison genes, we provided the genes previously determined to be mutated in human syndromes with CDH, including *WT1*, *GPC3*, *CHD7*, *NIPBL*, *EFNB1*, *LRP2*, *DLL3*, *FBNI*, *CHRNA3*, *STRA6* and *HCCS* (Entezami et al. 1998; Bulman et al. 2000; Li et al. 2001; Revencu et al. 2004; Vissers et al. 2004; Vasudevan et al. 2006; Wimplinger et al. 2006; Kantarci et al. 2007; Pasutto et al. 2007; Antonius et al. 2008), and genes known to be associated with diaphragmatic defects in null mice, including *Fog2*, *Slit3*, *Robo1* and *Lox* (Hornstra et al. 2003; Yuan et al. 2003; Ackerman et al. 2005). We used all of the Ref Seq genes from chromosome 4, nucleotides 1–2,406,426 (numbering according to hg 18; UCSC Genome Browser, <http://genome.ucsc.edu>) as the candidate genes, using the location of D4S43 to provide the outer boundary of the test region (Casaccia et al. 2006; UCSC genome browser <http://genome.ucsc.edu/>). Although the results of both programs were not entirely in agreement, both programs ranked *Fgfr11* highly, and the finding of diaphragmatic defects in mice that were homozygous null for *Fgfr11* led to our selection of this gene for initial study.

### Patients

DNA samples were obtained from patients with diaphragmatic defects using two protocols approved by the Committee for Human Subjects Research (CHR) at the University of California, San Francisco (UCSF; CHR numbers H41842-22157-07 and H41842-26613-05). We used 54 DNA samples from patients with isolated diaphragmatic hernias (the ethnic mix of this group was 48 Caucasian, 33 Hispanic, 7 African American, 6 Asian and 6% unknown or mixed) and 55 samples from patients with diaphragmatic hernia and additional anomalies

(the ethnic mix of this group was 44 Hispanic, 36 Caucasian, 9 Asian, 7 African American and 4% other/unknown). None of the patients with additional anomalies had been diagnosed with an underlying genetic syndrome as an explanation for their diaphragmatic defect. Some of these patient samples were derived from dried neonatal blood specimens obtained by the California Birth Defects Monitoring Program as part of a larger genetic investigation of risk factors of birth defects. Use of the human specimens for the purposes of the main study and the current sub-study was approved by the California Committee for the Protection of Human Subjects. The control samples comprised 109 samples from patients of Caucasian ethnicity without known diaphragmatic defects or skeletal anomalies (Rieckmann et al. 2008).

### Genomic sequencing

We sequenced the exons and the exon–intron boundaries of coding region for the *FGFRL1* gene in an initial group of 54 patients with isolated CDH. For selected single nucleotide polymorphisms (SNPs) (p. Pro20Pro, p.Pro362Gln, p. Arg424Leu, p. Pro464Leu), we genotyped additional patients who had CDH and additional anomalies to make a total of 200 genotyped chromosomes. We examined 80–100 bp of the 5' untranslated region upstream from the start codon of *FGFRL1*, but the promoter was not studied. We obtained data on the frequency of *FGFRL1* SNPs in controls by sequencing 109 control patients as described above and by examining the published SNP frequency in public databases (dbSNP; <http://www.ncbi.nlm.nih.gov/sites/entrez>). We used a two-tailed Fisher's exact test to compare the allele frequencies for the *FGFRL1* SNPs between CDH patients and controls. We used PolyPhen (<http://genetics.bwh.harvard.edu/pph/>) to predict the functional effect of non-synonymous SNPs in *FGFRL1*.

### cDNA array hybridization

We used GeneChip® Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) to hybridize three independently obtained cDNA samples from *Fgfr1l* null mice and *Fgfr1l* wildtype mice from three separate experiments. These gene chips contain 750,000, unique 25-mer oligonucleotide probes that interrogate 28,853 murine genes with an average of 27 probes across the full length of each gene ([http://www.affymetrix.com/products\\_services/arrays/specific/mousegene\\_1\\_st.affx](http://www.affymetrix.com/products_services/arrays/specific/mousegene_1_st.affx)). All of the probes map to exons that are well supported as coding regions of known genes.

RNA samples were obtained from murine fetuses at E18.5 and genotyped to establish sex and *Fgfr1l* status. RNA was treated with DNase (Invitrogen, Carlsbad, CA, USA) and cDNA samples were amplified, hybridized, washed and stained according to the manufacturer's specifications (GeneChip WT cDNA synthesis and amplification kit, Applied Biosystems, Carlsbad, CA, USA) by the J. David Gladstone Institutes Genomics Core Facility at UCSF (<http://www.gladstone.ucsf.edu/gladstone/php/?site-name=genomicscore>). Negative controls were performed by replacing RNA with RNase-free water.

### Gene expression analysis

Basic processing, quality control and normalization of the six Affymetrix Mouse Gene 1.0 ST chips were done at the Swiss Institute for Bioinformatics in Lausanne using Affymetrix Power Tools ([http://www.affymetrix.com/partners\\_programs/programs/developer/tools/powertools.affx](http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.affx)). The processed chips were found to be of good quality since in each case the probe set relative log expression mean was between 0.1 and 0.23, and because no clear outlier was observed (Fig. 1). Differentially expressed genes were identified utilizing linear models (limma) and Benjamini–Hochberg correction for multiple testing. Only genes with adjusted *p* values of less than 0.1 were further investigated.

## Reverse transcription-polymerase chain reaction (RT-PCR) with SybrGreen

We used SYBRGreen and RT-PCR to quantify *Fgfr1l* and *Myh4* expression from the diaphragm of wildtype and knockout mice. cDNA from *Fgfr1l* null and wildtype mice was obtained from total RNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Primer pairs were *Myh4* forward primer: CGAAGGCGGAGCTACGGT, *Myh4* reverse primer: GGCCATGTCCTCAATCTTGTC; *Fgfr1l* forward primer: ACAAGGCCGGTGCCATCAAC; *Fgfr1l* reverse primer: TGGAACGAGTCCGCTGGATT. PCR was conducted in triplicate with 20  $\mu$ L reaction volumes of water, PerfeCTa SYBR Green SuperMix Reaction Mixes (Quanta Biosciences Inc., Gaithersburg, MD, USA) with Rox as a passive reference, 5 ng cDNA, and 0.9–0.15 mM each primer depending on optimization of the primer set. Water and SYBR Green Supermix were aliquoted into individual tubes, one for each cDNA sample. cDNA was then added to the aliquoted Supermix and water. The combined Supermix, water and cDNA was then aliquoted into a 384-well plate. The primers and water were mixed together and added to the Supermix, water, and cDNA in the 384-well plate. PCR was conducted on the ABI 7900HT (Applied Biosystems) using the following cycle parameters: 1 cycle of 95° for 3 min, 40 cycles of 95° for 15 s, 60° for 1 min, and 1 cycle of 95° for 15 s, 60° for 15 s, 95° for 15 s. Analysis was carried out using the SDS software (version 2.3) supplied with the ABI 7900HT to determine the Ct values of each reaction. A dissociation curve was run after amplification to ensure the amplification of a single product. Ct values were determined for three test and three reference reactions in each sample, averaged, and subtracted to obtain the  $\Delta$ Ct [ $\Delta$ Ct = Ct (test locus) – Ct (control locus)]. PCR efficiencies were measured for all custom assays and were greater than or equal to 90%. Therefore, relative fold difference was calculated for each primer/probe combination as  $2^{-\Delta$ Ct}  $\times$  100. *Gapdh* was used as a control.

### Taqman probe analysis

cDNA from *Fgfr1l* null and wildtype mice was obtained from total RNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). The expression of *Tpm3* (Taqman probe Mm00445589\_m1; Applied Biosystems), *Myl3* (Taqman probe Mm00803032\_m1), *Lrtm1* (Taqman probe Mm00620949\_m1), *Myh7* (TaqMan probe Mm00600555\_m1) and *Myl2* (TaqMan probe Mm00440384\_m1) were run according to protocol of the manufacturer using an ABI Prism 7500 sequence detection system (Applied Biosystems). All reactions were run in sets of four identical reactions. *Hprt* expression (TaqMan probe Mm03024075\_m1) did not differ significantly in expression between *Fgfr1l* null and wildtype mice, and was used as a control (data not shown). Quantification analysis was performed as above using the  $\Delta\Delta$ Ct method using *Hprt* as a control.

## Results

### Gene prioritization software

Using all of the available Endeavour databases and the training gene set listed above and Endeavour prioritization software, *FGFRL1* returned as the gene with the highest prioritization score from the 43 genes and transcripts contained within the 2.4-Mb interval on chromosome 4p16.3 (Table 2). Using TOPPgene, *FGFRL1* ranked third with a *p* value of 0.193, behind *SPON2* (*p* = 0.008) and *FGFR3* (*p* = 0.02) (Table 2). However, a mouse model of loss of *Spon2* (also known as *mindin*) function showed no evidence of pulmonary or diaphragmatic defects, although the gene is expressed in fetal and adult lungs (He et al. 2004). Mice with *Fgfr3* loss of function have had severe kyphosis, long tails, curved femurs and loss of the inner pillar cells of the ear, consistent with the function of *Fgfr3* as an inhibitor of chondrocyte proliferation, but the *Fgfr3* null mice have not had CDH or diaphragmatic abnormalities (Colvin et al. 1996; Deng et al. 1996). After considering the available data from mouse models



of loss of gene function and both gene prioritization programs, we selected *Fgfr11* for our initial studies.

### Genomic sequencing

The SNPs identified in *FGFRL1* in patients with CDH and controls have been shown in Table 3. The allele frequencies for all of the SNPs were not significantly different from those expected with Hardy–Weinberg equilibrium in either patients or controls (data not shown). Our results confirmed six known coding SNPs in *FGFRL1*: c.209G > A (p.Pro20Pro), c.977G > A (p.P276P), c.1040T > C (p.Asp297Asp), c.1234C > A (p.Pro362Gln), c.1420G > T (p.Arg424Leu), and c.1540C > T (p.Pro464Leu). We did not identify any novel SNP or mutations in *FGFRL1* in either patients or controls. For c.209G > A, a synonymous SNP, the allele frequency in CDH patients was of borderline statistical significance ( $p = 0.048$ ) when compared to the allele frequency in control patients, but the allele frequencies in the CDH patients did not differ significantly from the allele frequencies found in craniosynostosis patients ( $p = 0.49$ ). The remainder of the allele frequencies for the coding SNPs did not differ significantly between patients with CDH and normal controls (Table 3). However, it is interesting that one patient with WHS, CDH and a 4p16.3 deletion including *FGFRL1* (Slavotinek et al. 2006) was also sequenced and was found to be hemizygous for the minor allele for three of the six SNPs (p. Pro20Pro, p. Pro362Gln, and p.Pro464Leu) on the remaining 4p16.3 allele. Although the first of these SNPs is synonymous, the second SNP returned a position-specific independent counts (PSIC) score difference of 1.854 with the interpretation of ‘possibly damaging’ by PolyPhen and the third SNP returned a PSIC score of 1.831 with the same interpretation of ‘possibly damaging’. It is therefore feasible that these SNPs resulted in reduced protein function on the intact allele of this patient, thus predisposing to diaphragmatic hypoplasia because of a further reduction in *FGFRL1* expression.

### cDNA array hybridization

We found only eight genes with significantly reduced expression levels ( $p < 0.05$ ) in *Fgfr11* homozygous null mice compared to wildtype mice (see Table 4 for Summary and Supplementary data for results of 200 genes). These genes were *Tpm3*, *Fgfr11* (as expected;  $p = 0.004$ ), *Myl2*, *Lrtm1*, *Myh4*, *Myl3*, *Myh7* and *Heph11*. We confirmed a reduction in the expression of *Tpm3*, *Myl3*, *Lrtm1*, *Myh7* and *Myl2* in homozygous null mice when compared with wildtype controls using Taqman probes and in *Fgfr11* and *Myh4* using SYBR Green and RT-PCR (Table 5). We were unable to verify the reduction in *Heph11* expression, as we could not reliably amplify this gene using SYBR Green and there was no commercially available Taqman probe. There were no genes that were significantly overexpressed in the *Fgfr11* homozygous null mice. *Fog2* (*Zfpm2*) and *Slit3*, two genes known to cause diaphragm hypoplasia in mice (Yuan et al. 2003; Ackerman et al. 2005), did not show significantly altered expression in the diaphragm of mutant mice compared to wildtype controls, with both genes having  $p$  values of 0.49 (Supplementary data).

### Discussion

The fibroblast growth factor receptors (FGFRs) share a canonical structure comprising an extracellular region with three immunoglobulin-like (Ig-like) domains, a stretch of acidic residues between the first and second Ig-like domains termed the acidic box, a transmembrane helix, and an intracellular domain with tyrosine kinase activity (Mohammadi et al. 2005). Binding of FGFs and heparan sulfate to the FGFRs induces dimerization (Mohammadi et al. 2005). An active complex of two FGFs, two FGFRs and one or two heparan sulfate chains results in trans-phosphorylation of specific tyrosine kinase residues in the intracellular domain of the FGFR, recruiting adapter proteins and enabling downstream signaling by diverse pathways including the PLC $\gamma$  pathway, P-I-3 Kinase-AKT/PKB pathway and the Ras-MAP

kinase pathway (Dailey et al. 2005). *Fgfr11* is the most diverged of the Fgfrs (Wiedemann and Trueb 2000; Kim et al. 2001). Although it is structurally related to the other Fgfrs, with the NH<sub>2</sub>-terminal of the protein having three Ig-like domains, six cysteines, an acidic box and one transmembrane domain, *Fgfr11* lacks both the histidine–alanine–valine motif that is critical for binding other FGFR molecules and the tyrosine kinase domain that is required for intracellular signaling (Wiedemann and Trueb 2001; Kim et al. 2001; Sleeman et al. 2001). *Fgfr11* is increased at sites of cell–cell contact and the protein is hypothesized to promote cell adhesion (Rieckmann et al. 2008). *Fgfr11* can therefore be considered similar to a nectin, a class of Ig-like, transmembrane cell adhesion molecule required for contact inhibition of cell movement and proliferation (Takai et al. 2008). Finally, there is some evidence that *Fgfr11* may act as a decoy receptor to coordinate the distribution of free FGF ligand and inhibit FGF signaling, as *Fgfr11* can inhibit the FGF-stimulated growth of MG63 cells (Trueb et al. 2003) and inhibit the FGF-stimulated activity of an FGF-inducible responsive element in a luciferase experiment (Rieckmann et al. 2009).

Our cDNA arrays examined comparative gene expression from the diaphragms of sex-matched, *Fgfr11* homozygous null mice and wildtype littermates at E18.5. The murine diaphragm forms between E11.5 and E13.5, (Leinwand et al. 2002), but E18.5 was chosen because of the ease of diaphragmatic dissection at this later stage of gestation. We also believe that an examination of this time period is still useful, as at least some genes that have been implicated in diaphragm development (for example, *Slit3* and *Fog2*), are expressed at this later stage of development in addition to earlier time periods. The expression of *Fgfr11* was reduced in the *Fgfr11* homozygous null mice compared to wildtype littermates (Table 4;  $p = 0.004$ ), validating the array methodology. Only seven genes besides *Fgfr11* showed significant decreases in expression level in the mutant diaphragms when compared with wildtype littermates: *Tpm3*, *Myl2*, *Lrtm1*, *Myh4*, *Myl3*, *Myh7* and *Heph11*. Tropomyosin-3 (*Tpm3*; OMIM 191030) showed the greatest reduction in expression in the *Fgfr11* mutant mice (Table 4). This gene encodes a component of the thin filaments of the sarcomere, and loss of function mutations in *TPM3* have been reported in patients with nemaline myopathy and congenital fiber type disproportion (Laing et al. 1995; Clarke et al. 2008; Lehtokari et al. 2008). Interestingly, diaphragm hypoplasia is a recognized complication of severe nemaline myopathy (Wada et al. 1996; Danhaive et al. 2007). However, in patients with *TPM3* loss of function mutations, the diameter of the type I slow fibers is reduced, as *TPM3* encodes the slow isoform of skeletal muscle  $\alpha$ -tropomyosin (Lehtokari et al. 2008). As the *Fgfr11* null mice had normal muscle fiber histology and the ratio of fiber subtypes was unaltered when compared with normal littermates (Baertschi et al. 2007), this suggests that the reduction in *Tpm3* expression in the *Fgfr11* null mice was a secondary phenomenon, attributable either to the deficiency of *Fgfr11* and/or to the muscular hypoplasia of the diaphragm.

The expression arrays also demonstrated reduced expression for four other genes that encode sarcomeric proteins: Myosin, light chain-2 (*Myl2*; OMIM 160781), Myosin, heavy chain-4 (*Myh4*; OMIM 160742), Myosin, light chain-3 (*Myl3*; OMIM 160790), and Myosin, heavy chain-7 (*Myh7*, OMIM 160760). *Myl3* and *Myh7* both encode slow-twitch, type I muscle isoforms (Jandreski et al. 1987), whereas *Myl2* regulates myosin ATPase activity in smooth muscle. Heterozygous, missense *Myl2* mutations have been described in hypertrophic cardiomyopathy (Poetter et al. 1996; Flavigny et al. 1998; Richard et al. 2003). Mutations in *Myh7* have also been described in hypertrophic and dilated cardiomyopathies (García-Castro et al. 2003; Richard et al. 2003; Hershberger et al. 2008; Møller et al. (2009) and have been estimated to account for up to 40–50% of hypertrophic cardiomyopathies. *Myh7* mutations have also been reported in myosin storage myopathy and Laing myopathy (Meredith et al. 2004), but diaphragm weakness is not a common component of these myopathies. *Myl3* mutations are rare in dilated and hypertrophic cardiomyopathies (Richard et al. 2003; Fokstuen et al. 2008; Møller et al. (2009), whereas mutations in *Myh4* have not been reported in cardiac

disease. We were not able to find any link between mutations in these genes and diaphragmatic defects.

Increased expression of *Tpm3* and *Myh7*, both components of the slow-twitch fibers that predominate in the diaphragm, has previously been noted in wildtype diaphragms compared to wildtype hindlimbs in mice (Porter et al. 2004). As these genes are expressed in the muscular component of the developing diaphragm, it is plausible that the differences in expression seen for the sarcomere genes could be related to the muscular hypoplasia of the diaphragm per se, independent from *Fgfr11* expression, or the differences in expression could be related to the muscular hypoplasia of the diaphragm in addition to the absence of *Fgfr11* expression. For example, the reduced expression of *Tpm3* and the other sarcomere genes in the *Fgfr11* null diaphragms may reflect reduced myoblast adhesion and secondary diaphragm thinning due to the postulated role of *Fgfr11* in cell adhesion. However, at a minimum, our results demonstrate that the expression of these genes is important for the late stages of murine diaphragm development in utero.

Little is known regarding the functions of *Lrtm1* and *Heph11*, the remaining two differentially expressed genes from our array studies. Leucine-rich transmembrane protein 1 (*Lrtm1*) has three coding exons that produce a 356 amino acid membrane protein of unknown function (Kim et al. 2007). Transcripts have been isolated from many cDNAs from the pineal gland, lung and eye (Unigene; <http://www.ncbi.nlm.nih.gov/unigene>), and there does not seem to be an obvious relationship with muscle hypoplasia. A BlastP analysis (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) revealed that *Lrtm1* shows strong homology to Slit3 (1e-19) and Slit2 (4e-16), suggesting that *Lrtm1* and Slit3 could share a similar function. This is interesting, as *Slit3* homozygous null mice have diaphragmatic hernias resulting from a failure of the septum transversum, or central tendon, of the diaphragm, to separate from the liver (Yuan et al. 2003). Slit3 was localized to the plasma membrane and mitochondria of a macrophage cell line, RAW264.7, and inhibition of *Slit3* reduced cell motility and the activity of two small GTPases known to be involved in actin cytoskeleton organization, *Cdc42* and *Rac* (Begum et al. 2004; Tanno et al. 2007). *Rac1* and *Cdc42* have been shown to be essential for myoblast fusion in the diaphragm in conditional mutant mice (Vasyutina et al. 2009). Further studies are needed to investigate whether *Lrtm1* is also involved in cell motility or myoblast fusion in the diaphragm and to define its relationship with *Fgfr11*. The Slit proteins have also been shown to be important in axon guidance and cell migration (Ma and Tessier-Lavigne 2007). The protein similarity between *Lrtm1* and Slit3 is intriguing, as it suggests that there may be more than one gene with a role in cell migration that is important in diaphragm development, perhaps acting by providing guidance cues for muscle cell or muscle nerve cell migration, if *Lrtm1* does indeed share a similar function to Slit3.

The last gene, *Heph11*, has greatest similarity to *Hephaestin* (*Heph*; OMIM 300167), a gene encoding a transmembrane protein with ferroxidase activity that can function as an iron transporter in intestinal cells (Vulpe et al. 1999; Griffiths et al. 2005). *Heph* is mutated in sex-linked anemia (sla) mice that have a microcytic, hypochromic anemia with deficient export of iron from enterocytes (Petraik and Vyoral 2005), but *Heph* shows no known link with human disease and we were unable to find any connection between *Heph* and diaphragm development.

We chose to re-sequence *FGFRL1* in patients with CDH because of reports of two independent mouse models of loss of *Fgfr11* gene function that had muscular hypoplasia of distinct, distal regions of the diaphragm (Baertschi et al. 2007; Catela et al. 2009) and the finding of *FGFRL1* as a candidate gene for CDH associated with 4p deletions. Our re-sequencing studies did not identify any new sequence alterations in *FGFRL1* in CDH patients, nor did they demonstrate a significant difference in the frequency of SNPs between control and patient population groups (Table 3). Despite the relatively small number of genotyped patients, our



interpretation of the results is that the CDH patients studied were representative of this population and that further sequencing would be unlikely to uncover any significant differences from normal controls in terms of the allele frequencies for these SNPs in *FGFRL1*. In addition, several of the SNPs have relatively high heterozygosity scores (for example, see p.Pro20Pro and p.Pro362Gln; Table 3), thus making biological significance possibly less likely due to the relatively common frequency of carriers. However, one CDH patient who had a 4p16.3 deletion that included *FGFRL1* was hemizygous for the minor allele for three of the six SNPs, raising the possibility that the CDH in this patient may have been related to reduced *FGFRL1* expression caused by his deletion and these SNPs, or by the deletion of *FGFRL1* and at least one other gene at 4p16.3.

Sequencing of *FGFRL1* has previously been performed in 55 patients with congenital skeletal malformations comprising 22 patients with non-syndromic craniosynostosis and 19 with short stature (Rieckmann et al. 2008). In a female with a clinical diagnosis of Antley-Bixler syndrome (craniosynostosis, radio-ulnar synostosis and genital anomalies), a frameshift mutation in exon 6 of *FGFRL1* caused by an insertion of four nucleotides was identified (Rieckmann et al. 2008). The mutant and wildtype protein both localized to the plasma membrane, but the mutant protein lacked a sorting signal and was not removed from the plasma membrane as quickly, enabling interactions with FGF ligands of a longer duration and thus suggesting a gain of function, in contrast to *Fgfr1* wildtype protein, which was removed from the plasma membrane more quickly (Rieckmann et al. 2008). This patient was also re-sequenced for P450 oxidoreductase mutations, a gene known to cause Antley-Bixler syndrome, and a missense mutation, p. Ala287Pro, and a novel mutation at the 3' splice junction of exon 8 changing the donor sequence AGgtacca into AGatacca (Rieckmann et al. 2008) were identified. There are no other published re-sequencing studies of the *FGFRL1* gene. Our failure to detect mutations or significant polymorphisms in *FGFRL1* in CDH patients could be construed as further evidence that diaphragm hypoplasia can be a pathologically and genetically distinct process from CDH.

## Conclusion

We studied *FGFRL1* as a candidate gene for the diaphragmatic defects found with monosomy for 4p16.3 and in WHS. Re-sequencing of this gene showed no novel mutations or SNPs that were significantly associated with CDH. However, our cDNA expression arrays showed a significant decrease in the expression level of *Lrtm1* and several sarcomere genes in E18.5 diaphragms from *Fgfr1* homozygous null mice when compared with wildtype littermates. *Lrtm1* shows similarity with *Slit3*, a gene involved in cell motility that has previously been implicated in hernias involving the central tendon of the murine diaphragm, and that can alter the expression of two genes, *Rac* and *Cdc42*, that are essential for myoblast fusion. It remains to be seen whether *Lrtm1* has a similar function to *Slit3*, and if *Fgfr1* therefore might cause diaphragm hypoplasia through a mechanism involving cell motility and/or myoblast fusion.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Anne Slavotinek was generously funded by a K08 grant HD053476-01A1 from the National Institute of Child Health and Development (NICHD) at the National Institutes of Health. Dr Beat Trueb was supported by a Swiss National Science Foundation grant, 3100A0-113806. We are grateful to the Genome Analysis Core Facility and the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, for their help with the RT-PCR experiments. This publication was supported by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. The findings and conclusions in this report are solely the responsibility of the authors and do not necessarily represent the official

views of the NIH or the California Department of Public Health. We thank the California Department of Public Health Maternal Child and Adolescent Health Division for providing data for these analyses.

## References


- Ackerman KG, Herron BJ, Vargas SO, Huang H, Tevosian SG, Kochilas L, Rao C, Pober BR, Babiuk RP, Epstein JA, Greer JJ, Beier DR. Fog2 is required for normal diaphragm and lung development in mice and humans. *PLoS Genet* 2005;1:58–65. [PubMed: 16103912]
- Antonius T, van Bon B, Eggink A, van der Burgt I, Noordam K, van Heijst A. Denys-Drash syndrome and congenital diaphragmatic hernia: another case with the 1097G > A(Arg366His) mutation. *Am J Med Genet A* 2008;146A:496–499. [PubMed: 18203154]
- Baertschi S, Zhuang L, Trueb B. Mice with a targeted disruption of the Fgfr1 gene die at birth due to alterations in the diaphragm. *FEBS J* 2007;274:6241–6253. [PubMed: 17986259]
- Basgul A, Kavak ZN, Akman I, Basgul A, Gokaslan H, Elcioglu N. Prenatal diagnosis of Wolf–Hirschhorn syndrome (4p-) in association with congenital diaphragmatic hernia, cystic hygroma and IUGR. *Clin Exp Obstet Gynecol* 2006;33:105–106. [PubMed: 16903248]
- Begum R, Nur-E-Kamal MS, Zaman MA. The role of Rho GTP-ases in the regulation of the rearrangement of actin cytoskeleton and cell movement. *Exp Mol Med* 2004;36:358–366. [PubMed: 15365255]
- Bulman MP, Kusumi K, Frayling TM, McKeown C, Garrett C, Lander ES, Krumlauf R, Hattersley AT, Ellard S, Turnpenny PD. Mutations in the human delta homologue, DLL3, cause axial skel-etal defects in spondylocostal dysostosis. *Nat Genet* 2000;24:438–441. [PubMed: 10742114]
- Casaccia G, Mobili L, Braguglia A, Santoro F, Bagolan P. Distal 4p microdeletion in a case of Wolf–Hirschhorn syndrome with congenital diaphragmatic hernia. *Birth Defects Res A Clin Mol Teratol* 2006;76:210–213. [PubMed: 16498629]
- Catela C, Bilbao-Cortes D, Slonimsky E, Kratsios P, Rosenthal N, Te Welscher P. Multiple congenital malformations of Wolf–Hirschhorn syndrome are recapitulated in Fgfr1 null mice. *Dis Model Mech* 2009;2:283–294. [PubMed: 19383940]
- Clarke NF, Kolski H, Dye DE, Lim E, Smith RL, Patel R, Fahey MC, Bellance R, Romero NB, Johnson ES, Labarre-Vila A, Monnier N, Laing NG, North KN. Mutations in TPM3 are a common cause of congenital fiber type disproportion. *Ann Neurol* 2008;63:329–337. [PubMed: 18300303]
- Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat Genet* 1996;12:390–397. [PubMed: 8630492]
- Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. *Cytokine Growth Factor Rev* 2005;16:233–234. [PubMed: 15863038]
- Danhaive O, Lozzi S, D'amico A, Devito R, Boldrini R, Corchia C, Bagolan P, Bertini E. Neonatal-onset nemaline myopathy mimicking congenital diaphragmatic hernia. *J Pediatr Surg* 2007;42:E19–E22. [PubMed: 17618867]
- Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* 1996;84:911–912. [PubMed: 8601314]
- Engbers H, van der Smagt JJ, van 't Slot R, Vermeesch JR, Hochstenbach R, Poot M. Wolf–Hirschhorn syndrome facial dysmorphic features in a patient with a terminal 4p16.3 deletion telomeric to the WHSCR and WHSCR 2 regions. *Eur J Hum Genet* 2009;17:129–132. [PubMed: 18830230]
- Entezami M, Runkel S, Kunze J, Weitzel HK, Becker R. Prenatal diagnosis of a lethal multiple pterygium syndrome type II. Case report. *Fetal Diagn Ther* 1998;13:35–38. [PubMed: 9605614]
- Flavigny J, Richard P, Isnard R, Carrier L, Charron P, Bonne G, Forissier JF, Desnos M, Dubourg O, Komajda M, Schwartz K. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. *J Mol Med* 1998;76:208–214. [PubMed: 9535554]
- Fokstuen S, Lyle R, Munoz A, Gehrig C, Lerch R, Perrot A, Osterziel KJ, Geier C, Beghetti M, Mach F, Sztajzel J, Sigwart U, Antonarakis SE, Blouin JL. A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. *Hum Mutat* 2008;29:879–885. [PubMed: 18409188]
- García-Castro M, Reguero JR, Batalla A, Díaz-Molina B, González P, Alvarez V, Cortina A, Cubero GI, Coto E. Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain

- (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. *Clin Chem* 2003;49:1279–1285. [PubMed: 12881443]
- Griffiths TA, Mauk AG, MacGillivray RT. Recombinant expression and functional characterization of human hephaestin: a multicopper oxidase with ferroxidase activity. *Biochemistry* 2005;44:14725–14731. [PubMed: 16274220]
- Hall C, Flores MV, Murison G, Crosier K, Crosier P. An essential role for zebrafish *Fgf11* during gill cartilage development. *Mech Dev* 2006;123:925–940. [PubMed: 17011755]
- He YW, Li H, Zhang J, Hsu CL, Lin E, Zhang N, Guo J, Forbush KA, Bevan MJ. The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. *Nat Immunol* 2004;5:88–97. [PubMed: 14691481]
- Hershberger RE, Parks SB, Kushner JD, Li D, Ludwigsen S, Jakobs P, Nauman D, Burgess D, Partain J, Litt M. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. *Clin Transl Sci* 2008;1:21–22. [PubMed: 19412328]
- Holder AM, Klaassens M, Tibboel D, de Klein A, Lee B, Scott DA. Genetic factors in congenital diaphragmatic hernia. *Am J Hum Genet* 2007;80:825–845. [PubMed: 17436238]
- Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. *J Biol Chem* 2003;278:14387–14393. [PubMed: 12473682]
- Howe DT, Kilby MD, Sirry H, Barker GM, Roberts E, Davison EV, Mchugo J, Whittle MJ. Structural chromosome anomalies in congenital diaphragmatic hernia. *Prenat Diagn* 1996;16:1003–1009. [PubMed: 8953633]
- Jandreski MA, Sole MJ, Liew CC. Two different forms of beta myosin heavy chain are expressed in human striated muscle. *Hum Genet* 1987;77:127–131. [PubMed: 3653886]
- Kantarci S, Casavant D, Prada C, Russell M, Byrne J, Haug LW, Jennings R, Manning S, Blaise F, Boyd TK, Fryns JP, Holmes LB, Donahoe PK, Lee C, Kimonis V, Pober BR. Findings from aCGH in patients with congenital diaphragmatic hernia (CDH): a possible locus for Fryns syndrome. *Am J Med Genet A* 2006;140:17–23. [PubMed: 16333846]
- Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, Loscertales M, Robson C, Liu T, MacLaughlin DT, Noonan KM, Russell MK, Walsh CA, Donahoe PK, Pober BR. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. *Nat Genet* 2007;39:957–959. [PubMed: 17632512]
- Kim I, Moon S, Yu K, Kim U, Koh GY. A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas(1). *Biochim Biophys Acta* 2001;1518:152–156. [PubMed: 11267671]
- Kim HG, Higgins AW, Herrick SR, Kishikawa S, Nicholson L, Kutsche K, Ligon AH, Harris DJ, Macdonald ME, Bruns GA, Morton CC, Quade BJ, Gusella JF. Candidate loci for Zimmermann-Laband syndrome at 3p14.3. *Am J Med Genet A* 2007;143:107–111. [PubMed: 17163523]
- Laing NG, Wilton SD, Akkari PA, Dorosz S, Boundy K, Kneebone C, Blumbergs P, White S, Watkins H, Love DR, et al. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy NEM1. *Nat Genet* 1995;10(2):249. [PubMed: 7663526]
- Lazjuk GI, Lurie IW, Ostrowskaja TI, Kirillova IA, Nedzved MK, Cherstvoy ED, Silyaeva NF. The Wolf-Hirschhorn syndrome. II. Pathologic anatomy. *Clin Genet* 1980;18:6–12. [PubMed: 7418255]
- Lehtokari VL, Pelin K, Donner K, Voit T, Rudnik-Schöneborn S, Stoetter M, Talim B, Topaloglu H, Laing NG, Wallgren-Pettersson C. Identification of a founder mutation in TPM3 in nemaline myopathy patients of Turkish origin. *Eur J Hum Genet* 2008;16:1055–1061. [PubMed: 18382475]
- Leinwand MJ, Tefft JD, Zhao J, Coleman C, Anderson KD, Warburton D. Nitrofen inhibition of pulmonary growth and development occurs in the early embryonic mouse. *J Pediatr Surg* 2002;37:1263–1268. [PubMed: 12194114]
- Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, Stevens C, Wilkins-Haug L, Day-Salvatore D, Yong SL, Geraghty MT, Squire J, Weksberg R. GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. *Am J Med Genet* 2001;102:161–168. [PubMed: 11477610]

- Ma L, Tessier-Lavigne M. Dual branch-promoting and branch-repelling actions of Slit/Robo signaling on peripheral and central branches of developing sensory axons. *J Neurosci* 2007;27:6843–6851. [PubMed: 17581972]
- Meredith C, Herrmann R, Parry C, Liyanage K, Dye DE, Durling HJ, Duff RM, Beckman K, de Visser M, van der Graaff MM, Hedera P, Fink JK, Petty EM, Lamont P, Fabian V, Bridges L, Voit T, Mastaglia FL, Laing NG. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1). *Am J Hum Genet* 2004;75:703–708. [PubMed: 15322983]
- Mohammadi M, Olsen SK, Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. *Curr Opin Struct Biol* 2005;15:506–516. [PubMed: 16154740]
- Møller DV, Andersen PS, Hedley P, Ersbøll MK, Bundgaard H, Moolman-Smook J, Christiansen M, Køber L. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. *Eur J Hum Genet* (Epub ahead of print). 2009
- Pasutto F, Sticht H, Hammersen G, Gillessen-Kaesbach G, Fitzpatrick DR, Nürnberg G, Brasch F, Schirmer-Zimmermann H, Tolmie JL, Chitayat D, Houge G, Fernández-Martínez L, Keating S, Mortier G, Hennekam RC, von der Wense A, Slavotinek A, Meinecke P, Bitoun P, Becker C, Nürnberg P, Reis A, Rauch A. Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation. *Am J Hum Genet* 2007;80:550–560. [PubMed: 17273977]
- Petrak J, Vyoral D. Hephaestin—a ferroxidase of cellular iron export. *Int J Biochem Cell Biol* 2005;37:1173–1178. [PubMed: 15778082]
- Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, Sellers JR, Fananapazir L, Epstein ND. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. *Nat Genet* 1996;13:63–69. [PubMed: 8673105]
- Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, Cheng G, Khanna S. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. *Hum Mol Genet* 2004;13:257–269. [PubMed: 14681298]
- Revenu N, Quenum G, Detaille T, Verellen G, De Paepe A, Verellen-Dumoulin C. Congenital diaphragmatic eventration and bilateral uretero-hydronephrosis in a patient with neonatal Marfan syndrome caused by a mutation in exon 25 of the FBN1 gene and review of the literature. *Eur J Pediatr* 2004;163:33–37. [PubMed: 14586646]
- Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burbani M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation* 2003;107:2227–2232. [PubMed: 12707239]
- Rieckmann T, Kotevic I, Trueb B. The cell surface receptor FGFR1 forms constitutive dimers that promote cell adhesion. *Exp Cell Res* 2008;314:1071–1081. [PubMed: 18061161]
- Rieckmann T, Zhuang L, Flück CE, Trueb B. Characterization of the first FGFR1 mutation identified in a craniosynostosis patient. *Biochim Biophys Acta* 2009;1792:112–121. [PubMed: 19056490]
- Scott DA, Klaassens M, Holder AM, Lally KP, Fernandes CJ. Genome-wide oligonucleotide-based array comparative genome hybridization analysis of non-isolated congenital diaphragmatic hernia. *Hum Mol Genet* 2007;16:424–430. [PubMed: 17210672]
- Sergi C, Schulze BR, Hager HD, Beedgen B, Zilow E, Linderkamp O, Otto HF, Tariverdian G. Wolf-Hirschhorn syndrome: case report and review of the chromosomal aberrations associated with diaphragmatic defects. *Pathologica* 1998;90:285–293. [PubMed: 9774859]
- Slavotinek AM, Moshrefi A, Davis R, Leeth E, Schaeffer GB, Burchard GE, Shaw GM, James B, Ptacek L, Pennacchio LA. Array comparative genomic hybridization in patients with congenital diaphragmatic hernia: mapping of four CDH-critical regions and sequencing of candidate genes at 15q26.1–15q26.2. *Eur J Hum Genet* 2006;14:999–1008. [PubMed: 16736036]

- Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. Identification of a new fibroblast growth factor receptor, FGFR5. *Gene* 2001;271:171–182. [PubMed: 11418238]
- Soussi-Yanicostas N, Whalen RG, Petit C. Five skeletal myosin heavy chain genes are organized as a multigene complex in the human genome. *Hum Mol Genet* 1993;2:563–569. [PubMed: 8518795]
- Tachdjian G, Fondacci C, Tapia S, Hutten Y, Blot P, Nessmann C. The Wolf–Hirschhorn syndrome in fetuses. *Clin Genet* 1992;42:281–287. [PubMed: 1493641]
- Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. *Nat Rev Mol Cell Biol* 2008;9:603–615. [PubMed: 18648374]
- Tanno T, Fujiwara A, Sakaguchi K, Tanaka K, Takenaka S, Tsuyama S. Slit3 regulates cell motility through Rac/Cdc42 activation in lipopolysaccharide-stimulated macrophages. *FEBS Lett* 2007;581:1022–1026. [PubMed: 17306799]
- Tapper JK, Zhang S, Harirah HM, Panova NI, Merryman LS, Hawkins JC, Lockhart LH, Gei AB, Velagaleti GV. Prenatal diagnosis of a fetus with unbalanced translocation (4;13)(p16;q32) with overlapping features of Patau and Wolf-Hirschhorn syndromes. *Fetal Diagn Ther* 2002;17:347–351. [PubMed: 12393964]
- Trueb B, Taeschler S. Expression of FGFR1, a novel fibroblast growth factor receptor, during embryonic development. *Int J Mol Med* 2006;17:617–620. [PubMed: 16525717]
- Trueb B, Zhuang L, Taeschler S, Wiedemann M. Characterization of FGFR1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues. *J Biol Chem* 2003;278:33857–33865. [PubMed: 12813049]
- Van Buggenhout G, Melotte C, Dutta B, Froyen G, Van Hummelen P, Marynen P, Matthijs G, de Ravel T, Devriendt K, Fryns JP, Vermeesch JR. Mild Wolf–Hirschhorn syndrome: micro-array CGH analysis of atypical 4p16.3 deletions enables refinement of the genotype-phenotype map. *J Med Genet* 2004;41:691–698. [PubMed: 15342700]
- van Dooren MF, Brooks AS, Hoozeboom AJ, van den Hoonaard TL, de Klein JE, Wouters CH, Tibboel D. Early diagnosis of Wolf–Hirschhorn syndrome triggered by a life-threatening event: congenital diaphragmatic hernia. *Am J Med Genet A* 2004;127:194–196. [PubMed: 15108210]
- Vasudevan PC, Twigg SR, Mulliken JB, Cook JA, Quarrell OW, Wilkie AO. Expanding the phenotype of craniofrontonasal syndrome: two unrelated boys with EFNB1 mutations and congenital diaphragmatic hernia. *Eur J Hum Genet* 2006;14:884–887. [PubMed: 16639408]
- Vasyutina E, Martarelli B, Brakebusch C, Wende H, Birchmeier C. The small G-proteins Rac1 and Cdc42 are essential for myoblast fusion in the mouse. *Proc Natl Acad Sci USA* 2009;106:8935–8940. [PubMed: 19443691]
- Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, van der Vliet WA, Huys EH, de Jong PJ, Hamel BC, Schoenmakers EF, Brunner HG, Veltman JA, van Kessel AG. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat Genet* 2004;36:955–957. [PubMed: 15300250]
- Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet* 1999;21:195–199. [PubMed: 9988272]
- Wada H, Nishio H, Kugo M, Waku S, Ikeda K, Takada S, Murakami R, Itoh H, Matsuo M, Nakamura H. Severe neonatal nemaline myopathy with delayed maturation of muscle. *Brain Dev* 1996;18:135–138. [PubMed: 8733906]
- Wiedemann M, Trueb B. Characterization of a novel protein (FGFR1) from human cartilage related to FGF receptors. *Genomics* 2000;69:275–279. [PubMed: 11031111]
- Wiedemann M, Trueb B. The mouse Fgfr1 gene coding for a novel FGF receptor-like protein. *Biochim Biophys Acta* 2001;1520:247–250. [PubMed: 11566361]
- Wimplinger I, Morleo M, Rosenberger G, Iaconis D, Orth U, Meinecke P, Lerer I, Ballabio A, Gal A, Franco B, Kutsche K. Mutations of the mitochondrial holocytochrome c-type synthase in X-linked dominant microphthalmia with linear skin defects syndrome. *Am J Hum Gene* 2006;79:878–889.
- Yuan W, Rao Y, Babiuk RP, Greer JJ, Wu JY, Ornitz DM. A genetic model for a central (septum transversum) congenital diaphragmatic hernia in mice lacking Slit3. *Proc Natl Acad Sci USA* 2003;100:5217–5222. [PubMed: 12702769]





**Fig. 1.** Comparison of gene expression levels in wildtype diaphragm at E18.5 (*X*-axis) compared to knock-out—wildtype diaphragm gene expression (*Y*-axis) from three independent experiments. There are few significant outliers over a range of genes with low expression to high expression

Table 1

Summary of diaphragmatic defects in patients with monosomy for chromosome 4p16

Patient	Clinical diagnosis	Karyotype	Mapping; estimated size	Diaphragm defect	Pulmonary hypoplasia	Reference
Case A	WHS	Not done	Not done	CDH, type not described	L lung	Lazjuk et al. (1980)
Case B	WHS	Not done	Not done	CDH, type not described	L lung	Lazjuk et al. (1980)
Case 5	WHS	46,XY,del(4)(p16)	Not done	CDH, L-sided	Bilateral	Tachdjian et al. (1992)
-	WHS	46,XX,der(4)t(4;13)(p16;q32),ish,der(4)t(4;13)(p16;q32)(WHS-)	Not done	CDH, type not described	Not mentioned	Tapper et al. (2002)
-	WHS	46,XX,del(4)(p16)	Not done	CDH, type not described	Not mentioned	Howe et al. (1996)
-	Dandy-Walker malformation; facial cleft	46,XX,del(4)(p16)	Not done	CDH, type not described	Not mentioned	Howe et al. (1996)
-	WHS	46,XX,del(4)(pter → 13)	Not done	CDH, L-sided	Bilateral	Sergi et al. (1998)
-	WHS	46,XX,ish del(4)(p16.1)	RP274B16 (deleted) RP11-173B23 (not deleted)	CDH, L-sided Bochdalek	Bilateral	Van Dooren et al. (2004)
Patient 1	WHS	46,XX,del(4)(p16.3)	RP513G18 (deleted); RP11-489M13 (not deleted); 3.81 Mb	CDH, L-sided	Not mentioned	Van Buggenhout et al. (2004)
-	WHS	46,XX,del(4)(p15.2)	Not done	CDH		Basgul et al. (2006)
-	WHS	46,XX,ish del(4)(p16.3)	D4S43 to telomere; 2.4 Mb	CDH, L-sided	Not mentioned	Casaccia et al. (2006)
-	WHS	46,XX,del(4)(p16)	RP11-97H19 (deleted); RP11-101J14 (not deleted); 8 Mb	CDH, L-sided	Bilateral	Slavotinek et al. (2006)

WHS Wolf-Hirschhorn syndrome, CDH congenital diaphragmatic hernia, L left, L-sided left-sided

**Table 2**

Gene prioritization rankings for diaphragmatic hernia using Endeavour and TOPPgene software programs

Ranking	Endeavour <sup>a</sup>	TOPPgene <sup>b</sup>	Overall <i>p</i> value (TOPPgene only) <sup>b</sup>
1	<i>FGFRL1</i>	<i>SPON2</i>	0.008
2	<i>FGFR3</i>	<i>FGFR3</i>	0.020
3	<i>IDUA</i>	<i>FGFRL1</i>	0.193
4	<i>WHSC1</i>	<i>TACC3</i>	0.244
5	<i>CTBP1</i>	<i>WHSC1</i>	0.291
6	<i>MAEA</i>	<i>RNF212</i>	0.652
7	<i>SPON2</i>	<i>KIAA1530</i>	0.658
8	<i>MXD4</i>	<i>TMEM175</i>	0.701

Only the top eight ranked genes are shown

<sup>a</sup>Endeavour (<http://homes.esat.kuleuven.be/~bioiuser/endeavour/endeavour.php>)

<sup>b</sup>TOPPgene prioritization software (<http://toppgene.cchmc.org/>)

**Table 3**  
Coding and non-coding sequence alterations in *FGFR1* in patients with diaphragmatic hernia

<i>FGFR1</i> Exon	Nucleotide	Amino acid	dbSNP	Allele frequency in diaphragmatic hernia patients (number of chromosomes)	Allele frequency in control patients (number of chromosomes)	Allele frequency in craniosynostosis patients from dbSNP (number of chromosomes)
2	c.209G > A	p.Pro20Pro	rs4647942	G = 0.58 (202) A = 0.42	G = 0.709 (86) A = 0.291	G = 0.525 (40) A = 0.475
5	c.727G > T	p.Arg193Leu	rs4647937	G = 1.0 (108) T = 0	G = 1 (84) T = 0	G = 1.0 (40) T = 0
6	c.977G > A	p.Pro276Pro	rs58679007	G = 0.99 (100) A = 0.01	G = 1 (84) A = 0	Not available
6	c.1040T > C	p.Asp297Asp	rs4647946	T = 0.98 (180) C = 0.02	T = 0.99 (218) C = 0.01	T = 0.95 (40) C = 0.05
7	c.1234C > A	p.Pro362Gln	rs4647930	C = 0.79 (200) A = 0.21	C = 0.725 (218) A = 0.275	C = 0.725 (40) A = 0.275
7	c.1420G > T	p.Arg424Leu	rs4647931	G = 0.96 (200) T = 0.04	G = 0.97 (216) T = 0.03	Not available
7	c.1540C > T	p.Pro464Leu	rs4647932	C = 0.92 (200) T = 0.08	C = 0.93 (216) T = 0.07	C = 0.925 (40) T = 0.075
<i>FGFR1</i> Intron	Nucleotide	Amino acid	dbSNP	Allele frequency in diaphragmatic hernia patients (n number of chromosomes)	Allele frequency in control patients (n number of chromosomes)	Allele frequency in craniosynostosis patients from dbSNP (n number of chromosomes)
IVS3	+16G > A	-	-	G = 0.95 (104) A = 0.05	G = 0.92 (176) A = 0.08	Not available
IVS4	+10G > C	-	rs4647933	G = 0.99 (92) C = 0.01	G = 0.99 (172) C = 0.01	G = 0.95 (40) C = 0.05
IVS6	+47G > A	-	rs4647944	G = 0.93 (108) A = 0.07	G = 0.94 (218) A = 0.06	T = 0.925 (40) A = 0.075
IVS6	+76G > T	-	-	G = 0.98 (102) T = 0.02	G = 0.995 (218) T = 0.005	Not available

dbSNP <http://www.ncbi.nlm.nih.gov/sites/entrez>

Table 4

Comparative gene expression between *FGFR1* null mice and wildtype littermates

Gene	Array <i>p</i> value	Array expression level in <i>FGFR1</i> null mice relative to wildtype mice	Function	Disease associated with loss of function	Reference(s)
<i>Tpm3</i>	0.0015	-2.34	Skeletal muscle contraction	AD, AR, Nemaline myopathy	Danhaive et al. (2007), Lehtokari et al. (2008), Wada et al. (1996)
<i>Fgf11</i>	0.0038	-2.0	Cell adhesion	Diaphragm hypoplasia	Baertschi et al. (2007), Catela et al. (2009)
<i>My12</i>	0.0100	-3.34	Cardiac and smooth muscle contraction	Cardiomyopathy	Flavigny et al. (1998), Richard et al. (2003)
<i>Lrml</i>	0.0117	-1.73	Unknown	Candidate gene for Zimmerman-Laband syndrome	Kim et al. (2007)
<i>Myh4</i>	0.0216	-1.89	Skeletal muscle contraction	None known	Soussi-Yanicostas et al. (1993)
<i>My13</i>	0.0216	-2.65	Skeletal muscle contraction	Cardiomyopathy	Richard et al. (2003), Fokstuen et al. (2008), Møller et al. (2009)
<i>Myh7</i>	0.0216	-2.27	Skeletal muscle contraction	Cardiomyopathy	García-Castro et al. (2003), Richard et al. (2003), Meredith et al. (2004), Hershberger et al. (2008), Møller et al. (2009)
<i>Heph1</i>	0.0478	-1.05	Unknown	None known	Nil

AD autosomal dominant, AR autosomal recessive



**Table 5**

Results for RT-PCR using SYBR-Green and Taqman probes for genes with reduced expression in *Fgfr11* null mice

Gene	Ct (avg.)	$\Delta Ct = \text{avg. Ct (gene)} - \text{avg. Ct } G\alpha dh$	Relative % expression normalized to <i>Gαdh</i> (Sybr) = $2^{-\Delta Ct} * 100$	Relative expression normalized to knock-out $2^{\Delta \Delta Ct}$
<i>Fgfr11</i> knock-out	33.93	9.65	0.12	1.0
<i>Fgfr11</i> wildtype	28.27	4.7	3.85	30.89
<i>Lrtm1</i> knock-out	37.59	13.3	0.01	1.0
<i>Lrtm1</i> wildtype	33.14	9.57	0.13	13.31
<i>Myh4</i> knock-out	38.19	13.9	0.01	1.0
<i>Myh4</i> wildtype	32.05	8.48	0.28	42.93

Gene	Ct (avg.)	$\Delta Ct = \text{avg. Ct (gene)} - \text{avg. Ct } Hprt$	Relative % expression normalized to <i>Hprt</i> (Taqman) = $2^{-\Delta Ct} * 100$	Relative expression normalized to knock-out $2^{\Delta \Delta Ct}$
<i>Myl2</i> knock-out	32.3	-1.35	255.03	1.0
<i>Myl2</i> wildtype	26.99	-5.69	5156.15	20.22
<i>Myh7</i> knock-out	29.06	-4.59	2402.89	1.0
<i>Myh7</i> wildtype	25.41	-7.29	15414.77	6.42
<i>Tpm3</i> knock-out	33.02	-3.28	973.60	1.0
<i>Tpm3</i> wildtype	28.42	-7.37	16582.21	17.03
<i>Myl3</i> knock-out	35.19	-1.11	215.90	1.0
<i>Myl3</i> wildtype	30.78	-5.01	3224.98	14.94

RT-PCR reverse transcription polymerase chain reaction, avg. average, Ct cycle threshold